Join Growin Stock Community!

Lifecore biomedical, inc.LFCR.US Overview

US StockHealthcare
(No presentation for LFCR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LFCR AI Insights

LFCR Overall Performance

LFCR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LFCR Recent Performance

-1.04%

Lifecore biomedical, inc.

0.05%

Avg of Sector

-0.31%

S&P500

LFCR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LFCR Key Information

LFCR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LFCR Profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Price of LFCR

LFCR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LFCR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.09
PB Ratio
192.10
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
31.57%
Net Margin
-24.01%
Revenue Growth (YoY)
9.25%
Profit Growth (YoY)
-0.62%
3-Year Revenue Growth
-10.47%
3-Year Profit Growth
10.20%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.09
PB Ratio
192.10
Price-to-FCF
-
Gross Margin
31.57%
Net Margin
-24.01%
Revenue Growth (YoY)
9.25%
Profit Growth (YoY)
-0.62%
3-Year Revenue Growth
-10.47%
3-Year Profit Growth
10.20%
  • When is LFCR's latest earnings report released?

    The most recent financial report for Lifecore biomedical, inc. (LFCR) covers the period of 2026Q1 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LFCR's short-term business performance and financial health. For the latest updates on LFCR's earnings releases, visit this page regularly.

  • What is the operating profit of LFCR?

    According to the latest financial report, Lifecore biomedical, inc. (LFCR) reported an Operating Profit of -3.07M with an Operating Margin of -9.86% this period, representing a growth of 73.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LFCR's revenue growth?

    In the latest financial report, Lifecore biomedical, inc. (LFCR) announced revenue of 31.11M, with a Year-Over-Year growth rate of 25.92%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does LFCR have?

    At the end of the period, Lifecore biomedical, inc. (LFCR) held Total Cash and Cash Equivalents of 18.86M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LFCR go with three margins increasing?

    In the latest report, Lifecore biomedical, inc. (LFCR) did not achieve the “three margins increasing” benchmark, with a gross margin of 25%%, operating margin of -9.86%%, and net margin of -35.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LFCR's profit trajectory and future growth potential.

  • Is LFCR's EPS continuing to grow?

    According to the past four quarterly reports, Lifecore biomedical, inc. (LFCR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LFCR?

    Lifecore biomedical, inc. (LFCR)'s Free Cash Flow (FCF) for the period is 25K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100.62% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.